USFDA Completes Records Assessment at Dr. Reddy鈥檚 Mexico Facility with Two Observations
Dr Reddys Laboratories Ltd 路 Others (Uncategorized) 路 12 Sept 2026, 3:37 am
USFDA Completes Records Assessment at Dr. Reddy鈥檚 Mexico Facility with Two Observations The USFDA concluded a records assessment under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act for Dr. Reddy鈥檚 Laboratories' API manufacturing facility in Jiutepec, Morelos, Mexico (Industrias Qu铆micas Falc贸n de M茅xico). Conducted between 17th Jul'26 and 8th Sep'26, the inspection resulted in the issuance of a Form FDA 2953 with two observations. The company stated it will respond to the observations within the stipulated timeline.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 14 Nov 2026
- Intimation of Analyst meet 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 05 Nov 2026
- Allotment of Employee Stock options 路 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... 路 03 Nov 2026
- Transcript of Earnings call 路 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 28 Oct 2026
